{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:27Z","timestamp":1790740227446,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin was compared with that of anidulafungin, caspofungin, micafungin, amphotericin B and fluconazole, using CLSI broth microdilution methodology (Fourth Edition: M27).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rezafungin MIC90 values were 0.06\u2009mg\/L for Candida albicans (n=125), Candida tropicalis (n=51), Candida dubliniensis (n=22), Candida inconspicua (n=41), Candida sojae (n=10), Candida lipolytica (n=10) and Candida pulcherrima (n=10), 0.12\u2009mg\/L for Candida glabrata (n=81), Candida krusei (n=53), Candida kefyr (n=52) and Candida fabianii (n=15), 0.25\u2009mg\/L for Candida lusitaniae (n=46) and Candida auris (n=19), 0.5\u2009mg\/L for Candida metapsilosis (n=15) and S. cerevisiae (n=21), 1\u2009mg\/L for Candida orthopsilosis (n=15) and Candida guilliermondii (n=27) and 2\u2009mg\/L for Candida parapsilosis sensu stricto (n=59). Caspofungin MIC90 values were 0.25\u20132\u2009mg\/L for all species, while micafungin and anidulafungin MIC90 values were similar to those of rezafungin. Fluconazole resistance was found in C. albicans (5.6%) and C. glabrata (4.9%); rezafungin was effective against these isolates as well. Amphotericin B MIC values did not exceed 2\u2009mg\/L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rezafungin showed excellent in vitro activity against both WT and azole-resistant Candida species, as well as against S. cerevisiae. Rezafungin had similar activity to other echinocandins (excluding caspofungin) against common Candida species and, notably, against clinically relevant uncommon Candida species.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkz390","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T11:28:52Z","timestamp":1565954932000},"page":"3505-3510","source":"Crossref","is-referenced-by-count":80,"title":["In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae"],"prefix":"10.1093","volume":"74","author":[{"given":"Zolt\u00e1n","family":"T\u00f3th","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Forg\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Locke","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc., 6310 Nancy Ridge Dr., Suite 101, San Diego, CA, 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Kardos","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fruzsina","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1t\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"},{"name":"Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Szekely","sequence":"additional","affiliation":[{"name":"UK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Borman","sequence":"additional","affiliation":[{"name":"UK National Mycology Reference Laboratory (MRL), Public Health England South-West, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Majoros","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"2019122310292581600_dkz390-B1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"2019122310292581600_dkz390-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2019122310292581600_dkz390-B3","doi-asserted-by":"crossref","first-page":"e02045-16","DOI":"10.1128\/AAC.02045-16","article-title":"Activity of long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 Antifungal Surveillance Program","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019122310292581600_dkz390-B4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2019122310292581600_dkz390-B5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2019122310292581600_dkz390-B6","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1128\/JCM.41.11.5250-5253.2003","article-title":"Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures","volume":"41","author":"Majoros","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2019122310292581600_dkz390-B7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkn403","article-title":"Comparison of killing activity of caspofungin against Candida parapsilosis, C. orthopsilosis and C. metapsilosis","volume":"62","author":"Varga","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019122310292581600_dkz390-B8","doi-asserted-by":"crossref","DOI":"10.1099\/jmmcr.0.000032","article-title":"Cyberlindnera fabianii in the neonatal and paediatric intensive care unit: case reports","volume":"2","author":"Mlinari\u0107-Missoni","year":"2015","journal-title":"JMM Case Reports"},{"key":"2019122310292581600_dkz390-B9","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/JCM.02350-07","article-title":"Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification","volume":"46","author":"Szab\u00f3","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2019122310292581600_dkz390-B10","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts","year":"2017"},{"key":"2019122310292581600_dkz390-B11","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","year":"2017"},{"key":"2019122310292581600_dkz390-B12","volume-title":"Epidemiological Cutoff Values for Antifungal Susceptibility Testing","year":"2018"},{"key":"2019122310292581600_dkz390-B13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JCM.00248-12","article-title":"Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019122310292581600_dkz390-B14","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/JCM.05047-11","article-title":"Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2019122310292581600_dkz390-B15","year":"2019"},{"key":"2019122310292581600_dkz390-B16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-014-0286-5","article-title":"Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management","volume":"74","author":"Perlin","year":"2014","journal-title":"Drugs"},{"key":"2019122310292581600_dkz390-B17","doi-asserted-by":"crossref","first-page":"e01541-16","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019122310292581600_dkz390-B18","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019122310292581600_dkz390-B19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/JCM.02659-15","article-title":"Effects of treated versus untreated polystyrene on caspofungin in vitro activity against Candida species","volume":"54","author":"Fothergill","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2019122310292581600_dkz390-B20","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997-2016","volume":"6 Suppl 1","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3505\/30795266\/dkz390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3505\/30795266\/dkz390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T22:06:31Z","timestamp":1610834791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/12\/3505\/5572326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,9,20]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz390","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,9,20]]}}}